Devising new strategies to track and prevent breast cancer development in BRCA mutation carriers
The overall goal of this project is to better understand the earliest stages of BRCA cancer development, in order to design strategies to prevent its progression to frank cancer. Dr. Joan Brugge’s laboratory studies the mechanisms of cancer initiation, progression, and drug resistance in breast, ovarian and other BRCA-related cancers. Specifically, Brugge’s team investigates tumor heterogeneity, cell-cell interactions, tumor microenvironment, cancer metabolism, drug resistance, and cell signaling using wide collection of tools, including 3D/organoid cell cultures, genetically-engineered and transplantation-based animal models, single-cell analysis, metabolomics, high-throughput microscopy, and other advanced technologies.
Contents
Project Overview
Team
- Project Lead: Joan Brugge, PhD
- Team: Aparicio, Dillon, Lin, Santagata, Garber, Venkitaraman
Research Questions
- How do basal and luminal breast cells contribute to BRCA-related cancers?
- How do BRCA tumor cells evolve?
- What are the molecular defects during tumor evolution?
- How do we detection cancer evolution in carriers?
- How do we intercept and eradicate tumor development?
Data Stories
Data Stories are data visualizations that guide readers through the complexities of a large dataset through filters, search, or narrated image waypoints.
Explore Tissue Images
Access the minimally processed, unannotated Level 2 images associated with this publication. Click any of the following thumbnail images for an interactive view of the full-resolution images.
